AMEERA-1: Subgroup Analyses of Phase I/Ii Study of Amcenestrant (Sar439859), an Oral Selective Estrogen Receptor (Er) Degrader (Serd), with Palbociclib in Postmenopausal Women with Er plus / Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Advanced Breast Cancer (Abc)